drugset / Trial / NCT05383196
Onvansertib + Paclitaxel In TNBC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research is being done to evaluate the safety and effectiveness of Onvansertib in combination with Paclitaxel in triple-negative breast cancer (TNBC) that has spread to other parts of the body. The names of the study interventions involved in this study are: * Onvansertib * Paclitaxel
Timeline
- Start
- 2022-09-30
- Primary completion
- 2026-12-15
- Completion
- 2029-02-15
Outcome
Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)
release “Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate” cardiffoncology.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Onvansertib | Small molecule | — | Oral |
| Background | Paclitaxel | Small molecule | — | Intravenous |